-
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
22 Oct 2025 20:08 GMT
On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire …
This strategic move accelerates Alkermes’ entry into the sleep … Alkermes’ portfolio of orexin 2 receptor agonists, including ALKS 4510 and ALKS … , present, or future patents that could be asserted …
-
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript
03 May 2025 12:50 GMT
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript May 1, 2025
Alkermes plc misses on … : Good morning. Welcome to the Alkermes Plc conference call to discuss our … for patients and long potential patent lives. This is why the …
-
Federal Circuit Lacks Jurisdiction Over Award That Doesn’t Raise Issue of Patent Law
07 Aug 2025 22:20 GMT
… issue of patent law. Acorda Therapeutics Inc. v. Alkermes PLC, Case … was unenforceable after the patent’s expiration and sought … was unenforceable after the patent’s expiration. However, … without judicial interpretation of patent law. The Federal Circuit …
-
Alkermes plc Reports First Quarter 2024 Financial Results
01 May 2024 14:29 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a global … IV" litigation and other patent litigation which may lead to …
-
Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript
16 Feb 2024 15:37 GMT
Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript February 15, 2024
Alkermes plc … morning. Welcome to the Alkermes plc conference call to discuss … relating to VIVITROL’s patent protection, which we … settlement of the VIVITROL patent matter, and most …
-
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
15 Feb 2024 12:38 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … the Janssen arbitration and VIVITROL patent litigation.
Balance Sheet
At Dec … IV" litigation and other patent litigation which may lead to …
-
Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript
26 Oct 2023 15:14 GMT
Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript October 25, 2023
Alkermes plc beats … successful settlement of the VIVITROL patent litigation, and the expected completion … with Teva to resolve our patent litigations related to VIVITROL. Under …
-
Alkermes plc Reports Third Quarter 2023 Financial Results
25 Oct 2023 14:39 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … successful settlement of the VIVITROL® patent litigation, and progress toward completion … , Inc. (Teva) to resolve the patent litigation between the parties related …
-
Alkermes plc Reports Second Quarter 2023 Financial Results
26 Jul 2023 14:05 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a fully … IV" litigation and other patent litigation which may lead to …
-
Alkermes plc Reports First Quarter 2023 Financial Results
26 Apr 2023 16:26 GMT
… /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for … be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a fully … IV" litigation and other patent litigation which may lead to …
About
© 1995-2026